Drug intelligence / Profile preview

FC-2.15

Development stage: Preclinical
Lead developer: Faculty of Medicine, University of Buenos Aires
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

FC-2.15 is a **monoclonal antibody** that specifically recognizes the Lewis x antigen (Le(x)-Ag) expressed on the cell surface of most human breast cancer cells. It exerts cytotoxic effects through complement-mediated cytotoxicity, targeting breast cancer cells that express the Le(x)-Ag. FC-2.15 has shown additive cytotoxicity when used in combination with chemotherapeutic agents such as adriamycin and taxol, making it a potential therapeutic for use in patients with breast cancers resistant to these drugs. The expression of the target antigen is retained even after standard chemotherapy[1].

Brand names: FC-2.15FC2.15FC 2.15
Other names: FC-2.15FC2.15FC 2.15

Targets

CD15 (CD15 antigen)

Beyond the preview

Go deeper on FC-2.15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FC-2.15.

Explore the full profile